Global Colon Cancer Market
Global Colon Cancer Market

Colon Cancer Comprehensive Study by Type (Surgery, Chemotherapy, Radiation), Application (Hospitals, Ambulatory Surgical Centers, Others), Testing Techniques (Macroscopy, Microscopy, Immunochemistry, Staging, Tumor Budding), Targeted Drugs (Bevacizumab (Avastin), Cetuximab (Erbitux), Panitumumab (Vectibix), Regorafenib (Stivarga)), Pharmacological Class (Phase 1 clinical trial, Phase 2 clinical trial, Phase 3 clinical trial) Players and Region - Global Market Outlook to 2024

Colon Cancer Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Feb 2019 Edition 228 Pages 162 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Colon Cancer Market Overview:
According to the Colon Cancer Alliance, colon cancer is the third most commonly diagnosed and second leading cause of cancer in the United States. Colon cancer/Colorectal Cancer is the cancer of large intestine which forms the lower part of the digestive system. Colon cancer usually begins with small, benign clusters of cells known as adenomatous polyps. If the disease is left untreated, these polyps may result into colon cancer. Therefore, regular screening for polyps through colonoscopy in order to prevent it transforming to colon cancer is recommended. Change in bowel habits or blood in stool are the major symptoms of colon cancer. Colorectal cancer (CRC) accounts for over 9% of all cancer incidences, and it is a major cause of morbidity and mortality throughout the world. CRC is the second most common cause of cancer-related deaths in the United States. Increasing cancer prevention initiatives and technological advancements in Radiology and Chemotherapy are driving the Global Colon Cancer market.

Market Drivers
  • Rising prevalence of colorectal cancer
  • Growing ageing population suffering from colon cancer
  • Introduction of new improved therapies and drugs.

Market Trend
  • Growing incidences of colon cancer and high pricing of products are attracting pharmaceutical companies to develop and market new products
  • Healthcare practitioners are cautioned with the cost-benefit ratio of colon cancer drugs owing to large presence in the market.

Restraints
  • Stringent regulatory norms and side effects of therapies used for the treatment may hamper the growth of the market.

Opportunities
  • High unmet demands in emerging economies and lack of adjuvant and non-adjuvant pipeline agents for the treatment of colon cancer is providing opportunity for the market.

Challenges
  • High-cost screening tests or drugs is posing a challenge for the market.


Competitive Landscape:
The nature of the vendor landscape is immensely competitive with multinational companies establishing a strong hold over the rest. The players are focused on devising successful strategies, such as competent marketing, expansion of geographical reach, prudent pricing, high investment in R&D, and offering clinical laboratory services. Such as National Nonprofit Colorectal Cancer Alliance is providing a total of USD 625,000 in grants to four researchers, including one advancing personalized treatment options for seeking to understand the root cause of rising colorectal cancer rates in patients under age 50. Product innovation is also viewed as one of the major growth strategies adopted by companies to gain a stronger foothold in the colon cancer market.
Some of the key players profiled in the report are F.Hoffman-La Roche Ltd. (Switzerland), Merck KGaA (Germany), Bayer HealthCare Pharmaceuticals (Germany), Boehringer Ingelheim (Germany), Taiho Pharmaceutical (Japan), Eli Lilly and Company (United States), Pfizer, Inc. (United States), Bedford Laboratories (United States), Teva Pharmaceuticals (Israel), Bermuda Cancer and Health Centre (Bermuda), Akanocure Pharmaceuticals, LLC (United States) and Siamab Therapeutics, Inc (United States). Additionally, following companies can also be profiled that are part of our coverage like Biomoti. Limited (United Kingdom), DNALite Therapeutics (United States), Corporate Health International ApS (United States) and Universal Diagnostics S.L (Spain). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Colon Cancer market by 2024. Considering Market by Testing Techniques, the sub-segment i.e. Macroscopy will boost the Colon Cancer market. Considering Market by Targeted Drugs, the sub-segment i.e. Bevacizumab (Avastin) will boost the Colon Cancer market. Considering Market by Pharmacological Class, the sub-segment i.e. Phase 1 clinical trial will boost the Colon Cancer market.

Market Highlights:

According to ESMO (European Society for Medical Oncology) 2018, In October 2018, Immunotherapy with Nivolumab and low-dose Ipilimumab can become a new first-line treatment in patients with some metastatic colorectal cancers. The drug combination shrank tumors and will have a beneficial effect on survival in patients with microsatellite Instabiliy (MSI)-high metastatic colorectal cancer.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Colon Cancer market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Colon Cancer market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Colon Cancer Drug Manufacturers, Government and Regulatory bodies, Pharmaceutical Companies and Distributors, Suppliers and Traders.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Surgery
  • Chemotherapy
  • Radiation
By Application
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
By Testing Techniques
  • Macroscopy
  • Microscopy
  • Immunochemistry
  • Staging
  • Tumor Budding

By Targeted Drugs
  • Bevacizumab (Avastin)
  • Cetuximab (Erbitux)
  • Panitumumab (Vectibix)
  • Regorafenib (Stivarga)

By Pharmacological Class
  • Phase 1 clinical trial
  • Phase 2 clinical trial
  • Phase 3 clinical trial

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of colorectal cancer
      • 3.2.2. Growing ageing population suffering from colon cancer
      • 3.2.3. Introduction of new improved therapies and drugs.
    • 3.3. Market Challenges
      • 3.3.1. High-cost screening tests or drugs is posing a challenge for the market.
    • 3.4. Market Trends
      • 3.4.1. Growing incidences of colon cancer and high pricing of products are attracting pharmaceutical companies to develop and market new products
      • 3.4.2. Healthcare practitioners are cautioned with the cost-benefit ratio of colon cancer drugs owing to large presence in the market.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Colon Cancer, by Type, Application, Testing Techniques, Targeted Drugs, Pharmacological Class and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Colon Cancer (Value)
      • 5.2.1. Global Colon Cancer by: Type (Value)
        • 5.2.1.1. Surgery
        • 5.2.1.2. Chemotherapy
        • 5.2.1.3. Radiation
      • 5.2.2. Global Colon Cancer by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Ambulatory Surgical Centers
        • 5.2.2.3. Others
      • 5.2.3. Global Colon Cancer by: Testing Techniques (Value)
        • 5.2.3.1. Macroscopy
        • 5.2.3.2. Microscopy
        • 5.2.3.3. Immunochemistry
        • 5.2.3.4. Staging
        • 5.2.3.5. Tumor Budding
      • 5.2.4. Global Colon Cancer by: Targeted Drugs (Value)
        • 5.2.4.1. Bevacizumab (Avastin)
        • 5.2.4.2. Cetuximab (Erbitux)
        • 5.2.4.3. Panitumumab (Vectibix)
        • 5.2.4.4. Regorafenib (Stivarga)
      • 5.2.5. Global Colon Cancer by: Pharmacological Class (Value)
        • 5.2.5.1. Phase 1 clinical trial
        • 5.2.5.2. Phase 2 clinical trial
        • 5.2.5.3. Phase 3 clinical trial
      • 5.2.6. Global Colon Cancer Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Colon Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F.Hoffman-La Roche Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer HealthCare Pharmaceuticals (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Taiho Pharmaceutical (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bedford Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceuticals (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bermuda Cancer and Health Centre (Bermuda)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Akanocure Pharmaceuticals, LLC (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Siamab Therapeutics, Inc (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Colon Cancer Sale, by Type, Application, Testing Techniques, Targeted Drugs, Pharmacological Class and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Colon Cancer (Value)
      • 7.2.1. Global Colon Cancer by: Type (Value)
        • 7.2.1.1. Surgery
        • 7.2.1.2. Chemotherapy
        • 7.2.1.3. Radiation
      • 7.2.2. Global Colon Cancer by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Ambulatory Surgical Centers
        • 7.2.2.3. Others
      • 7.2.3. Global Colon Cancer by: Testing Techniques (Value)
        • 7.2.3.1. Macroscopy
        • 7.2.3.2. Microscopy
        • 7.2.3.3. Immunochemistry
        • 7.2.3.4. Staging
        • 7.2.3.5. Tumor Budding
      • 7.2.4. Global Colon Cancer by: Targeted Drugs (Value)
        • 7.2.4.1. Bevacizumab (Avastin)
        • 7.2.4.2. Cetuximab (Erbitux)
        • 7.2.4.3. Panitumumab (Vectibix)
        • 7.2.4.4. Regorafenib (Stivarga)
      • 7.2.5. Global Colon Cancer by: Pharmacological Class (Value)
        • 7.2.5.1. Phase 1 clinical trial
        • 7.2.5.2. Phase 2 clinical trial
        • 7.2.5.3. Phase 3 clinical trial
      • 7.2.6. Global Colon Cancer Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Colon Cancer: by Type(USD Million)
  • Table 2. Colon Cancer Surgery , by Region USD Million (2013-2018)
  • Table 3. Colon Cancer Chemotherapy , by Region USD Million (2013-2018)
  • Table 4. Colon Cancer Radiation , by Region USD Million (2013-2018)
  • Table 5. Colon Cancer: by Application(USD Million)
  • Table 6. Colon Cancer Hospitals , by Region USD Million (2013-2018)
  • Table 7. Colon Cancer Ambulatory Surgical Centers , by Region USD Million (2013-2018)
  • Table 8. Colon Cancer Others , by Region USD Million (2013-2018)
  • Table 9. Colon Cancer: by Testing Techniques(USD Million)
  • Table 10. Colon Cancer Macroscopy , by Region USD Million (2013-2018)
  • Table 11. Colon Cancer Microscopy , by Region USD Million (2013-2018)
  • Table 12. Colon Cancer Immunochemistry , by Region USD Million (2013-2018)
  • Table 13. Colon Cancer Staging , by Region USD Million (2013-2018)
  • Table 14. Colon Cancer Tumor Budding , by Region USD Million (2013-2018)
  • Table 15. Colon Cancer: by Targeted Drugs(USD Million)
  • Table 16. Colon Cancer Bevacizumab (Avastin) , by Region USD Million (2013-2018)
  • Table 17. Colon Cancer Cetuximab (Erbitux) , by Region USD Million (2013-2018)
  • Table 18. Colon Cancer Panitumumab (Vectibix) , by Region USD Million (2013-2018)
  • Table 19. Colon Cancer Regorafenib (Stivarga) , by Region USD Million (2013-2018)
  • Table 20. Colon Cancer: by Pharmacological Class(USD Million)
  • Table 21. Colon Cancer Phase 1 clinical trial , by Region USD Million (2013-2018)
  • Table 22. Colon Cancer Phase 2 clinical trial , by Region USD Million (2013-2018)
  • Table 23. Colon Cancer Phase 3 clinical trial , by Region USD Million (2013-2018)
  • Table 24. South America Colon Cancer, by Country USD Million (2013-2018)
  • Table 25. South America Colon Cancer, by Type USD Million (2013-2018)
  • Table 26. South America Colon Cancer, by Application USD Million (2013-2018)
  • Table 27. South America Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 28. South America Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 29. South America Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 30. Brazil Colon Cancer, by Type USD Million (2013-2018)
  • Table 31. Brazil Colon Cancer, by Application USD Million (2013-2018)
  • Table 32. Brazil Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 33. Brazil Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 34. Brazil Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 35. Argentina Colon Cancer, by Type USD Million (2013-2018)
  • Table 36. Argentina Colon Cancer, by Application USD Million (2013-2018)
  • Table 37. Argentina Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 38. Argentina Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 39. Argentina Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 40. Rest of South America Colon Cancer, by Type USD Million (2013-2018)
  • Table 41. Rest of South America Colon Cancer, by Application USD Million (2013-2018)
  • Table 42. Rest of South America Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 43. Rest of South America Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 44. Rest of South America Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 45. Asia Pacific Colon Cancer, by Country USD Million (2013-2018)
  • Table 46. Asia Pacific Colon Cancer, by Type USD Million (2013-2018)
  • Table 47. Asia Pacific Colon Cancer, by Application USD Million (2013-2018)
  • Table 48. Asia Pacific Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 49. Asia Pacific Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 50. Asia Pacific Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 51. China Colon Cancer, by Type USD Million (2013-2018)
  • Table 52. China Colon Cancer, by Application USD Million (2013-2018)
  • Table 53. China Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 54. China Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 55. China Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 56. Japan Colon Cancer, by Type USD Million (2013-2018)
  • Table 57. Japan Colon Cancer, by Application USD Million (2013-2018)
  • Table 58. Japan Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 59. Japan Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 60. Japan Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 61. India Colon Cancer, by Type USD Million (2013-2018)
  • Table 62. India Colon Cancer, by Application USD Million (2013-2018)
  • Table 63. India Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 64. India Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 65. India Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 66. South Korea Colon Cancer, by Type USD Million (2013-2018)
  • Table 67. South Korea Colon Cancer, by Application USD Million (2013-2018)
  • Table 68. South Korea Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 69. South Korea Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 70. South Korea Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 71. Taiwan Colon Cancer, by Type USD Million (2013-2018)
  • Table 72. Taiwan Colon Cancer, by Application USD Million (2013-2018)
  • Table 73. Taiwan Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 74. Taiwan Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 75. Taiwan Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 76. Australia Colon Cancer, by Type USD Million (2013-2018)
  • Table 77. Australia Colon Cancer, by Application USD Million (2013-2018)
  • Table 78. Australia Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 79. Australia Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 80. Australia Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 81. Rest of Asia-Pacific Colon Cancer, by Type USD Million (2013-2018)
  • Table 82. Rest of Asia-Pacific Colon Cancer, by Application USD Million (2013-2018)
  • Table 83. Rest of Asia-Pacific Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 84. Rest of Asia-Pacific Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 85. Rest of Asia-Pacific Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 86. Europe Colon Cancer, by Country USD Million (2013-2018)
  • Table 87. Europe Colon Cancer, by Type USD Million (2013-2018)
  • Table 88. Europe Colon Cancer, by Application USD Million (2013-2018)
  • Table 89. Europe Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 90. Europe Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 91. Europe Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 92. Germany Colon Cancer, by Type USD Million (2013-2018)
  • Table 93. Germany Colon Cancer, by Application USD Million (2013-2018)
  • Table 94. Germany Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 95. Germany Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 96. Germany Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 97. France Colon Cancer, by Type USD Million (2013-2018)
  • Table 98. France Colon Cancer, by Application USD Million (2013-2018)
  • Table 99. France Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 100. France Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 101. France Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 102. Italy Colon Cancer, by Type USD Million (2013-2018)
  • Table 103. Italy Colon Cancer, by Application USD Million (2013-2018)
  • Table 104. Italy Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 105. Italy Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 106. Italy Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 107. United Kingdom Colon Cancer, by Type USD Million (2013-2018)
  • Table 108. United Kingdom Colon Cancer, by Application USD Million (2013-2018)
  • Table 109. United Kingdom Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 110. United Kingdom Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 111. United Kingdom Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 112. Netherlands Colon Cancer, by Type USD Million (2013-2018)
  • Table 113. Netherlands Colon Cancer, by Application USD Million (2013-2018)
  • Table 114. Netherlands Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 115. Netherlands Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 116. Netherlands Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 117. Rest of Europe Colon Cancer, by Type USD Million (2013-2018)
  • Table 118. Rest of Europe Colon Cancer, by Application USD Million (2013-2018)
  • Table 119. Rest of Europe Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 120. Rest of Europe Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 121. Rest of Europe Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 122. MEA Colon Cancer, by Country USD Million (2013-2018)
  • Table 123. MEA Colon Cancer, by Type USD Million (2013-2018)
  • Table 124. MEA Colon Cancer, by Application USD Million (2013-2018)
  • Table 125. MEA Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 126. MEA Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 127. MEA Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 128. Middle East Colon Cancer, by Type USD Million (2013-2018)
  • Table 129. Middle East Colon Cancer, by Application USD Million (2013-2018)
  • Table 130. Middle East Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 131. Middle East Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 132. Middle East Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 133. Africa Colon Cancer, by Type USD Million (2013-2018)
  • Table 134. Africa Colon Cancer, by Application USD Million (2013-2018)
  • Table 135. Africa Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 136. Africa Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 137. Africa Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 138. North America Colon Cancer, by Country USD Million (2013-2018)
  • Table 139. North America Colon Cancer, by Type USD Million (2013-2018)
  • Table 140. North America Colon Cancer, by Application USD Million (2013-2018)
  • Table 141. North America Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 142. North America Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 143. North America Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 144. United States Colon Cancer, by Type USD Million (2013-2018)
  • Table 145. United States Colon Cancer, by Application USD Million (2013-2018)
  • Table 146. United States Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 147. United States Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 148. United States Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 149. Canada Colon Cancer, by Type USD Million (2013-2018)
  • Table 150. Canada Colon Cancer, by Application USD Million (2013-2018)
  • Table 151. Canada Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 152. Canada Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 153. Canada Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 154. Mexico Colon Cancer, by Type USD Million (2013-2018)
  • Table 155. Mexico Colon Cancer, by Application USD Million (2013-2018)
  • Table 156. Mexico Colon Cancer, by Testing Techniques USD Million (2013-2018)
  • Table 157. Mexico Colon Cancer, by Targeted Drugs USD Million (2013-2018)
  • Table 158. Mexico Colon Cancer, by Pharmacological Class USD Million (2013-2018)
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Colon Cancer: by Type(USD Million)
  • Table 172. Colon Cancer Surgery , by Region USD Million (2019-2024)
  • Table 173. Colon Cancer Chemotherapy , by Region USD Million (2019-2024)
  • Table 174. Colon Cancer Radiation , by Region USD Million (2019-2024)
  • Table 175. Colon Cancer: by Application(USD Million)
  • Table 176. Colon Cancer Hospitals , by Region USD Million (2019-2024)
  • Table 177. Colon Cancer Ambulatory Surgical Centers , by Region USD Million (2019-2024)
  • Table 178. Colon Cancer Others , by Region USD Million (2019-2024)
  • Table 179. Colon Cancer: by Testing Techniques(USD Million)
  • Table 180. Colon Cancer Macroscopy , by Region USD Million (2019-2024)
  • Table 181. Colon Cancer Microscopy , by Region USD Million (2019-2024)
  • Table 182. Colon Cancer Immunochemistry , by Region USD Million (2019-2024)
  • Table 183. Colon Cancer Staging , by Region USD Million (2019-2024)
  • Table 184. Colon Cancer Tumor Budding , by Region USD Million (2019-2024)
  • Table 185. Colon Cancer: by Targeted Drugs(USD Million)
  • Table 186. Colon Cancer Bevacizumab (Avastin) , by Region USD Million (2019-2024)
  • Table 187. Colon Cancer Cetuximab (Erbitux) , by Region USD Million (2019-2024)
  • Table 188. Colon Cancer Panitumumab (Vectibix) , by Region USD Million (2019-2024)
  • Table 189. Colon Cancer Regorafenib (Stivarga) , by Region USD Million (2019-2024)
  • Table 190. Colon Cancer: by Pharmacological Class(USD Million)
  • Table 191. Colon Cancer Phase 1 clinical trial , by Region USD Million (2019-2024)
  • Table 192. Colon Cancer Phase 2 clinical trial , by Region USD Million (2019-2024)
  • Table 193. Colon Cancer Phase 3 clinical trial , by Region USD Million (2019-2024)
  • Table 194. South America Colon Cancer, by Country USD Million (2019-2024)
  • Table 195. South America Colon Cancer, by Type USD Million (2019-2024)
  • Table 196. South America Colon Cancer, by Application USD Million (2019-2024)
  • Table 197. South America Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 198. South America Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 199. South America Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 200. Brazil Colon Cancer, by Type USD Million (2019-2024)
  • Table 201. Brazil Colon Cancer, by Application USD Million (2019-2024)
  • Table 202. Brazil Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 203. Brazil Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 204. Brazil Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 205. Argentina Colon Cancer, by Type USD Million (2019-2024)
  • Table 206. Argentina Colon Cancer, by Application USD Million (2019-2024)
  • Table 207. Argentina Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 208. Argentina Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 209. Argentina Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 210. Rest of South America Colon Cancer, by Type USD Million (2019-2024)
  • Table 211. Rest of South America Colon Cancer, by Application USD Million (2019-2024)
  • Table 212. Rest of South America Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 213. Rest of South America Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 214. Rest of South America Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 215. Asia Pacific Colon Cancer, by Country USD Million (2019-2024)
  • Table 216. Asia Pacific Colon Cancer, by Type USD Million (2019-2024)
  • Table 217. Asia Pacific Colon Cancer, by Application USD Million (2019-2024)
  • Table 218. Asia Pacific Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 219. Asia Pacific Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 220. Asia Pacific Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 221. China Colon Cancer, by Type USD Million (2019-2024)
  • Table 222. China Colon Cancer, by Application USD Million (2019-2024)
  • Table 223. China Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 224. China Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 225. China Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 226. Japan Colon Cancer, by Type USD Million (2019-2024)
  • Table 227. Japan Colon Cancer, by Application USD Million (2019-2024)
  • Table 228. Japan Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 229. Japan Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 230. Japan Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 231. India Colon Cancer, by Type USD Million (2019-2024)
  • Table 232. India Colon Cancer, by Application USD Million (2019-2024)
  • Table 233. India Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 234. India Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 235. India Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 236. South Korea Colon Cancer, by Type USD Million (2019-2024)
  • Table 237. South Korea Colon Cancer, by Application USD Million (2019-2024)
  • Table 238. South Korea Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 239. South Korea Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 240. South Korea Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 241. Taiwan Colon Cancer, by Type USD Million (2019-2024)
  • Table 242. Taiwan Colon Cancer, by Application USD Million (2019-2024)
  • Table 243. Taiwan Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 244. Taiwan Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 245. Taiwan Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 246. Australia Colon Cancer, by Type USD Million (2019-2024)
  • Table 247. Australia Colon Cancer, by Application USD Million (2019-2024)
  • Table 248. Australia Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 249. Australia Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 250. Australia Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 251. Rest of Asia-Pacific Colon Cancer, by Type USD Million (2019-2024)
  • Table 252. Rest of Asia-Pacific Colon Cancer, by Application USD Million (2019-2024)
  • Table 253. Rest of Asia-Pacific Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 254. Rest of Asia-Pacific Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 255. Rest of Asia-Pacific Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 256. Europe Colon Cancer, by Country USD Million (2019-2024)
  • Table 257. Europe Colon Cancer, by Type USD Million (2019-2024)
  • Table 258. Europe Colon Cancer, by Application USD Million (2019-2024)
  • Table 259. Europe Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 260. Europe Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 261. Europe Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 262. Germany Colon Cancer, by Type USD Million (2019-2024)
  • Table 263. Germany Colon Cancer, by Application USD Million (2019-2024)
  • Table 264. Germany Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 265. Germany Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 266. Germany Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 267. France Colon Cancer, by Type USD Million (2019-2024)
  • Table 268. France Colon Cancer, by Application USD Million (2019-2024)
  • Table 269. France Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 270. France Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 271. France Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 272. Italy Colon Cancer, by Type USD Million (2019-2024)
  • Table 273. Italy Colon Cancer, by Application USD Million (2019-2024)
  • Table 274. Italy Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 275. Italy Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 276. Italy Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 277. United Kingdom Colon Cancer, by Type USD Million (2019-2024)
  • Table 278. United Kingdom Colon Cancer, by Application USD Million (2019-2024)
  • Table 279. United Kingdom Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 280. United Kingdom Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 281. United Kingdom Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 282. Netherlands Colon Cancer, by Type USD Million (2019-2024)
  • Table 283. Netherlands Colon Cancer, by Application USD Million (2019-2024)
  • Table 284. Netherlands Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 285. Netherlands Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 286. Netherlands Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 287. Rest of Europe Colon Cancer, by Type USD Million (2019-2024)
  • Table 288. Rest of Europe Colon Cancer, by Application USD Million (2019-2024)
  • Table 289. Rest of Europe Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 290. Rest of Europe Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 291. Rest of Europe Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 292. MEA Colon Cancer, by Country USD Million (2019-2024)
  • Table 293. MEA Colon Cancer, by Type USD Million (2019-2024)
  • Table 294. MEA Colon Cancer, by Application USD Million (2019-2024)
  • Table 295. MEA Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 296. MEA Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 297. MEA Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 298. Middle East Colon Cancer, by Type USD Million (2019-2024)
  • Table 299. Middle East Colon Cancer, by Application USD Million (2019-2024)
  • Table 300. Middle East Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 301. Middle East Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 302. Middle East Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 303. Africa Colon Cancer, by Type USD Million (2019-2024)
  • Table 304. Africa Colon Cancer, by Application USD Million (2019-2024)
  • Table 305. Africa Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 306. Africa Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 307. Africa Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 308. North America Colon Cancer, by Country USD Million (2019-2024)
  • Table 309. North America Colon Cancer, by Type USD Million (2019-2024)
  • Table 310. North America Colon Cancer, by Application USD Million (2019-2024)
  • Table 311. North America Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 312. North America Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 313. North America Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 314. United States Colon Cancer, by Type USD Million (2019-2024)
  • Table 315. United States Colon Cancer, by Application USD Million (2019-2024)
  • Table 316. United States Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 317. United States Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 318. United States Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 319. Canada Colon Cancer, by Type USD Million (2019-2024)
  • Table 320. Canada Colon Cancer, by Application USD Million (2019-2024)
  • Table 321. Canada Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 322. Canada Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 323. Canada Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 324. Mexico Colon Cancer, by Type USD Million (2019-2024)
  • Table 325. Mexico Colon Cancer, by Application USD Million (2019-2024)
  • Table 326. Mexico Colon Cancer, by Testing Techniques USD Million (2019-2024)
  • Table 327. Mexico Colon Cancer, by Targeted Drugs USD Million (2019-2024)
  • Table 328. Mexico Colon Cancer, by Pharmacological Class USD Million (2019-2024)
  • Table 329. Research Programs/Design for This Report
  • Table 330. Key Data Information from Secondary Sources
  • Table 331. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Colon Cancer: by Type USD Million (2013-2018)
  • Figure 5. Global Colon Cancer: by Application USD Million (2013-2018)
  • Figure 6. Global Colon Cancer: by Testing Techniques USD Million (2013-2018)
  • Figure 7. Global Colon Cancer: by Targeted Drugs USD Million (2013-2018)
  • Figure 8. Global Colon Cancer: by Pharmacological Class USD Million (2013-2018)
  • Figure 9. South America Colon Cancer Share (%), by Country
  • Figure 10. Asia Pacific Colon Cancer Share (%), by Country
  • Figure 11. Europe Colon Cancer Share (%), by Country
  • Figure 12. MEA Colon Cancer Share (%), by Country
  • Figure 13. North America Colon Cancer Share (%), by Country
  • Figure 14. Global Colon Cancer share by Players 2018 (%)
  • Figure 15. Global Colon Cancer share by Players (Top 3) 2018(%)
  • Figure 16. Global Colon Cancer share by Players (Top 5) 2018(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. F.Hoffman-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F.Hoffman-La Roche Ltd. (Switzerland) Revenue: by Geography 2018
  • Figure 20. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Merck KGaA (Germany) Revenue: by Geography 2018
  • Figure 22. Bayer HealthCare Pharmaceuticals (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer HealthCare Pharmaceuticals (Germany) Revenue: by Geography 2018
  • Figure 24. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Boehringer Ingelheim (Germany) Revenue: by Geography 2018
  • Figure 26. Taiho Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Taiho Pharmaceutical (Japan) Revenue: by Geography 2018
  • Figure 28. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 29. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 30. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer, Inc. (United States) Revenue: by Geography 2018
  • Figure 32. Bedford Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bedford Laboratories (United States) Revenue: by Geography 2018
  • Figure 34. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 35. Teva Pharmaceuticals (Israel) Revenue: by Geography 2018
  • Figure 36. Bermuda Cancer and Health Centre (Bermuda) Revenue, Net Income and Gross profit
  • Figure 37. Bermuda Cancer and Health Centre (Bermuda) Revenue: by Geography 2018
  • Figure 38. Akanocure Pharmaceuticals, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 39. Akanocure Pharmaceuticals, LLC (United States) Revenue: by Geography 2018
  • Figure 40. Siamab Therapeutics, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 41. Siamab Therapeutics, Inc (United States) Revenue: by Geography 2018
  • Figure 42. Global Colon Cancer: by Type USD Million (2019-2024)
  • Figure 43. Global Colon Cancer: by Application USD Million (2019-2024)
  • Figure 44. Global Colon Cancer: by Testing Techniques USD Million (2019-2024)
  • Figure 45. Global Colon Cancer: by Targeted Drugs USD Million (2019-2024)
  • Figure 46. Global Colon Cancer: by Pharmacological Class USD Million (2019-2024)
  • Figure 47. South America Colon Cancer Share (%), by Country
  • Figure 48. Asia Pacific Colon Cancer Share (%), by Country
  • Figure 49. Europe Colon Cancer Share (%), by Country
  • Figure 50. MEA Colon Cancer Share (%), by Country
  • Figure 51. North America Colon Cancer Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • F.Hoffman-La Roche Ltd. (Switzerland)
  • Merck KGaA (Germany)
  • Bayer HealthCare Pharmaceuticals (Germany)
  • Boehringer Ingelheim (Germany)
  • Taiho Pharmaceutical (Japan)
  • Eli Lilly and Company (United States)
  • Pfizer, Inc. (United States)
  • Bedford Laboratories (United States)
  • Teva Pharmaceuticals (Israel)
  • Bermuda Cancer and Health Centre (Bermuda)
  • Akanocure Pharmaceuticals, LLC (United States)
  • Siamab Therapeutics, Inc (United States)
Additional players considered in the study are as follows:
Biomoti. Limited (United Kingdom) , DNALite Therapeutics (United States) , Corporate Health International ApS (United States) , Universal Diagnostics S.L (Spain)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation